NASDAQ:ZSAN - Zosano Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.17
  • Forecasted Upside: 245.18 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.63
+0.30 (1.20%)

This chart shows the closing price for ZSAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zosano Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZSAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZSAN

Analyst Price Target is $2.17
▲ +245.18% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Zosano Pharma in the last 3 months. The average price target is $2.17, with a high forecast of $2.50 and a low forecast of $2.00. The average price target represents a 245.18% upside from the last price of $0.63.

This chart shows the closing price for ZSAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Zosano Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/30/2021HC WainwrightReiterated RatingBuy$2.00Medium
3/15/2021Maxim GroupBoost Price TargetBuy$1.50 ➝ $2.50Low
11/25/2020HC WainwrightLower Price TargetBuy$2.50 ➝ $2.00Low
10/22/2020BTIG ResearchLower Price TargetBuy$7.00 ➝ $2.00Low
10/2/2020Maxim GroupReiterated RatingBuy$2.00Low
10/2/2020HC WainwrightLower Price TargetBuy$4.00 ➝ $2.50Low
6/15/2020HC WainwrightReiterated RatingBuy$4.00High
5/20/2020Maxim GroupReiterated RatingBuyMedium
5/15/2020HC WainwrightReiterated RatingBuy$4.00Medium
4/19/2020HC WainwrightInitiated CoverageBuy$4.00Low
4/9/2020HC WainwrightInitiated CoverageBuy$4.00High
3/28/2020Maxim GroupReiterated RatingBuy$2.00Low
3/27/2020BTIG ResearchLower Price TargetBuy$16.00 ➝ $7.00Medium
3/7/2020Maxim GroupReiterated RatingBuy$2.00High
11/15/2019Maxim GroupReiterated RatingBuy$8.00Low
11/15/2019Cantor FitzgeraldLower Price TargetOverweight$12.00 ➝ $6.00Low
11/15/2019BTIG ResearchLower Price TargetBuy ➝ In-Line$16.00High
4/22/2019Cantor FitzgeraldInitiated CoverageOverweight$3.66High
4/17/2019Maxim GroupInitiated CoverageBuy ➝ Buy$8.00High
9/26/2018BTIG ResearchSet Price TargetBuy$19.00N/A
6/28/2018BTIG ResearchInitiated CoverageBuyHigh
3/24/2017Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
3/11/2017Roth CapitalSet Price TargetBuy$60.00Medium
2/14/2017Roth CapitalSet Price TargetBuy$40.00 ➝ $60.00N/A
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Zosano Pharma logo
Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The firm focuses on providing rapid systemic administration of therapeutics to patients using proprietary intracutaneous microneedle system. It offers Qtrypta, a formulation of zolmitriptan delivered utilizing the intracutaneous microneedle system. The company was founded in October 2006 and is headquartered in Fremont, CA.
Read More

Today's Range

Now: $0.63
Low: $0.62
High: $0.63

50 Day Range

MA: $0.69
Low: $0.60
High: $0.78

52 Week Range

Now: $0.63
Low: $0.33
High: $3.06

Volume

606,709 shs

Average Volume

4,682,591 shs

Market Capitalization

$72.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Zosano Pharma?

The following Wall Street sell-side analysts have issued research reports on Zosano Pharma in the last twelve months: BTIG Research, HC Wainwright, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for ZSAN.

What is the current price target for Zosano Pharma?

3 Wall Street analysts have set twelve-month price targets for Zosano Pharma in the last year. Their average twelve-month price target is $2.17, suggesting a possible upside of 245.2%. Maxim Group has the highest price target set, predicting ZSAN will reach $2.50 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $2.00 for Zosano Pharma in the next year.
View the latest price targets for ZSAN.

What is the current consensus analyst rating for Zosano Pharma?

Zosano Pharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZSAN will outperform the market and that investors should add to their positions of Zosano Pharma.
View the latest ratings for ZSAN.

How do I contact Zosano Pharma's investor relations team?

Zosano Pharma's physical mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company's listed phone number is (510) 745-1200 and its investor relations email address is [email protected] The official website for Zosano Pharma is www.zosanopharma.com.